Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
1995-05-02
2010-02-23
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S254100, C424S185100, C536S023700, C530S350000, C514S002600, C514S012200
Reexamination Certificate
active
07666436
ABSTRACT:
New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the amino acid residues Glu129, Asp11, Trp26, Arg9, Phe50, Asp1, Arg13, Tyr130, Gly86, Ile88, Tyr89, Tyr8, Gly44, Thr53 and Gly80 of subunit S1 amino acid sequence is deleted and substituted by a different amino acid residue selected in the group of natural amino acids;Bordetellastrains capable of providing and secreting said PT mutants and means and methods for obtaining them are also described. TheBordetellastrains and the PT mutants produced by them are particularly suitable for the preparation of effective cellular and acellular antipertussis vaccines.
REFERENCES:
patent: 4883761 (1989-11-01), Keith et al.
patent: 5085862 (1992-02-01), Klein et al.
patent: 5221618 (1993-06-01), Klein et al.
Barbieri et al., “ADP-Ribosyltransferase Mutations in the Catalytic S-1 Subunit of Pertussis Toxin,” Infection and Immunity, pp. 1934-1941, Aug. 1988.
Nicosia et al., “Cloning and sequencing of the pertussis toxin genes: Operon structure and gene duplication,” Proc. Natl. Acad. Sci. USA, vol. 83, pp. 4631-4635, Jul. 1986.
Pizza et al., “Mutants of Pertussis Toxin Suitable for Vaccine Development,” Science, vol. 246, pp. 497-500, Jul. 27, 1989.
Pizza et al., “Subunit S1 of pertussis toxin: Mapping of the regions essential for ADP-ribosyltransferase activity,” Proc. Natl. Acad. Sci. USA, vol. 85, pp. 7521-7525, Oct. 1988.
Loosmore et al., “Engineering of Genetically Detoxified Pertussis Toxin Analogs for Development of a Recombinant Whooping Cough Vaccine,” Infection and Immunity, pp. 3653-3662, Nov. 1990.
Podda et al., “Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa,” Vaccine, vol. 9, pp. 146-150, Oct. 1991.
Podda et al., “Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: Safety and immunogenicity in 12- to 24 and 2- to 4-month-old children,” Journal of Pediatrics, pp. 151-156, May 1992.
Del Giudice et al., “Priming to Heat Shock Proteins in Infants Vaccinated against Pertussis,” The Journal of Immunology, vol. 150, pp. 2025-2031, No. 5, Mar. 1993.
Podda et al., “Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine,” Journal of Pediatrics, pp. 921-926, Jun. 1994.
Zealey et al., “Construction ofBordetella pertussisStrains That Overproduce Genetically Inactivated Pertussis Toxin,” Applied and Environmental Microbiology, pp. 208-214, Jan. 1992.
Covacci Antonello
Nencioni Luciano
Pizza Mariagrazia
Rappuoli Rino
Gorman Robert
Groth Felicity E.
Kam Chih-Min
Novartis AG
LandOfFree
Pertussis toxin mutants, Bordetella strains capable of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pertussis toxin mutants, Bordetella strains capable of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pertussis toxin mutants, Bordetella strains capable of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197323